Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
83 hedge funds and large institutions have $208M invested in Adverum Biotechnologies in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 14 closing their positions.
4,750% more call options, than puts
Call options by funds: $194K | Put options by funds: $4K
72% more capital invested
Capital invested by funds: $121M → $208M (+$87.3M)
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
1.8% more ownership
Funds ownership: 61.14% → 62.94% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 86 → 83 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$5.03M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.82M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.72M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.9M |
| 5 |
JP Morgan Chase
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.04M |
| 2 |
Man Group
London,
United Kingdom
|
-$2.04M |
| 3 |
WM
WS Management
Jacksonville,
Florida
|
-$1.6M |
| 4 |
PA
Perceptive Advisors
New York
|
-$960K |
| 5 |
Two Sigma Investments
New York
|
-$801K |
ADVM Hedge Fund Activity: Q1 2019 in Review
83 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2019, worth a combined $208M — up 72% from $121M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ADVM and 11 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 26 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $5.03M. The largest seller was Citadel Advisors, cutting an estimated $6.04M.
- 83 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2019, down from 86 in Q4 2018.
- Funds reported $208M of Adverum Biotechnologies stock for Q1 2019, up 72% quarter-over-quarter.
- 11 funds opened new Adverum Biotechnologies positions in Q1 2019 and 14 closed out, a net change of -3 holders.
- The largest Adverum Biotechnologies buyer in Q1 2019 was OrbiMed, an estimated $5.03M added.
- The largest Adverum Biotechnologies seller in Q1 2019 was Citadel Advisors, an estimated $6.04M sold.
Based on aggregated 13F filings for Q1 2019.